NSCLC patients with high TREM2+ TAM infiltration had a lower objective response rate to ICT compared to patients with low numbers of TREM2+ TAMs and were more likely to experience tumor progression following PD-1 blockade (33). This evidence concerns the gene TREM2 and neoplasm.